Pancytopenia

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Pancytopenia is detected numerically but managed clinically. The three immediate consequences are impaired oxygen delivery, infection risk and bleeding risk. Severity depends on the actual haemoglobin, neutrophil and platelet counts, how rapidly they changed and the patient's reserve; the same values may be tolerated chronically but dangerous during sepsis or active bleeding. Ask about fever, mouth ulcers, bruising, mucosal bleeding, heavy menstruation, dyspnoea, chest pain and presyncope, then examine for infection, petechiae, purpura, lymphadenopathy, hepatosplenomegaly, bone tenderness and liver disease.

Mechanism is best organised as reduced production, ineffective production, marrow replacement or peripheral loss. Aplastic anaemia produces a hypocellular marrow and low reticulocytes. Megaloblastic deficiency and myelodysplasia can have cellular marrow but ineffective release. Leukaemia, lymphoma, fibrosis and metastases displace normal production. Sepsis, DIC, TMA, immune cytopenias and hypersplenism remove cells after production. More than one mechanism can coexist: alcohol may suppress marrow and cause portal splenic sequestration, while cancer treatment can add infection and drug toxicity.

The initial investigation is deliberately compact and high yield: repeat FBC, film, reticulocytes, haematinics, haemolysis, renal, liver and coagulation tests plus targeted infection, pregnancy and autoimmune testing. Bone marrow follows early when blasts, profound reticulocytopenia, progressive unexplained counts or a leucoerythroblastic pattern suggests a primary marrow disorder. Supportive transfusion and antimicrobials follow symptoms, bleeding and national or local protocols rather than automatic numerical correction. The final diagnosis must explain all three lineages and the clinical tempo.

Key points

Pancytopenia means reduction in red cells, white cells and platelets; it is a syndrome and does not specify whether the dominant mechanism is production failure, ineffective maturation, infiltration, consumption or sequestration.
Confirm the result and trajectory on a fresh FBC and expert film, but assess fever, bleeding, breathlessness, chest pain, syncope and neurological change before waiting for a repeat in an unwell patient.
Reticulocytes define the erythroid branch: a low response supports underproduction or ineffective erythropoiesis, while a raised response suggests red-cell loss or destruction with preserved erythroid capacity but does not by itself explain the white-cell and platelet reductions.
The film can reveal blasts, abnormal promyelocytes, macro-ovalocytes, hypersegmented neutrophils, schistocytes, teardrops, parasites or a leucoerythroblastic pattern and can make the pathway urgent.
Review every prescribed, non-prescribed and recreational exposure, including chemotherapy, immunosuppressants, antimicrobials, antiepileptics, alcohol and occupational or deliberate toxin exposure.
Severe B12 or folate deficiency can mimic marrow malignancy through cytopenia, high LDH and abnormal morphology; neurological B12 features require urgent replacement after diagnostic sampling.
Splenomegaly suggests sequestration, portal disease, infection or haematological malignancy, but hypersplenism remains a diagnosis integrated with marrow response and the cause of enlargement.
Bone-marrow aspiration and trephine are indicated when serious persistent pancytopenia remains unexplained or acute leukaemia, aplasia, myelodysplasia, fibrosis or infiltration is suspected.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Marrow production failure

Aplastic anaemia, severe B12 or folate deficiency, infection, alcohol, medicines, chemotherapy and radiation suppress progenitors or effective maturation across several lineages.

Marrow replacement

Acute leukaemia, myelodysplasia, lymphoma, myelofibrosis, metastatic cancer and granulomatous disease replace or distort normal haematopoietic space.

Peripheral loss or consumption

Sepsis, immune destruction, thrombotic microangiopathy, disseminated coagulation and major bleeding can reduce several circulating cell populations despite ongoing marrow effort.

Splenic sequestration

Portal hypertension, haematological disease and infection can enlarge the spleen, pooling red cells, white cells and platelets and shortening their circulation.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Stem-cell or precursor injury
Toxic, immune, infective or clonal damage reduces the number or function of marrow progenitors available to form mature blood cells.
2
Ineffective maturation
Defective DNA synthesis or dysplasia allows precursors to form but causes intramedullary death, producing low circulating counts despite a cellular marrow.
3
Architectural displacement
Fibrosis, malignant infiltration or granulomas occupy marrow niches and disrupt normal lineage organisation, maturation and release into peripheral blood.
4
Peripheral depletion
Consumption, immune clearance or splenic pooling removes circulating cells faster than marrow can replace them, sometimes producing a compensatory reticulocyte response.
5
Combined clinical failure
Anaemia impairs oxygen delivery, neutropenia weakens infection defence and thrombocytopenia compromises primary haemostasis, creating interacting rather than isolated risks.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Neutropenic sepsisRed flag

Fever, rigors, hypotension, confusion or focal infection with significant neutropenia is an emergency; inflammatory signs may be muted and treatment should follow the neutropenic-sepsis pathway.

Acute leukaemia phenotypeRed flag

Blasts or abnormal promyelocytes, bruising, infection, bone pain, gum change, lymphadenopathy or splenomegaly with rapidly evolving counts demands urgent haematology assessment.

Aplastic pattern

Severe cytopenias, low reticulocytes, few abnormal circulating cells and absence of major splenomegaly can indicate aplastic anaemia, confirmed by hypocellular trephine after exclusions.

Megaloblastic phenotype

Macrocytosis, oval macrocytes, hypersegmented neutrophils, glossitis or neurological findings with low B12 or folate supports ineffective DNA synthesis.

Consumption phenotypeRed flag

Sepsis, shock, thrombocytopenia, prolonged coagulation, falling fibrinogen or schistocytic haemolysis suggests DIC or TMA and redirects management from isolated marrow failure.

Hypersplenic phenotype

An enlarged spleen with portal, infective or clonal disease and less profound balanced cytopenias suggests pooling and increased removal, but does not exclude marrow involvement.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Repeat FBC, differential and expert filmFirst step
Why
Confirm multilineage abnormality, detect artefact and identify urgent morphology.
Interpretation and limitations
Blasts, abnormal promyelocytes, schistocytes, teardrops, hypersegmentation or parasites narrow the pathway. A normal-looking film does not exclude aplasia or patchy marrow disease.
02
Absolute reticulocyte count
Why
Distinguish impaired production from preserved marrow response to peripheral loss.
Interpretation and limitations
A low count supports failure or ineffective maturation. Reticulocytosis suggests bleeding, haemolysis or recovery, although iron, B12 or folate lack can blunt an otherwise expected response.
03
Ferritin, transferrin saturation, B12 and folate
Why
Identify correctable substrate deficiency and mixed anaemia.
Interpretation and limitations
Confirm deficiency using the appropriate national pathway. Folate alone can improve blood counts while B12 neurological injury progresses, so B12 safety comes first.
04
Haemolysis and coagulation profile
Why
Find immune, microangiopathic or consumptive loss affecting several lineages.
Interpretation and limitations
Reticulocytes, bilirubin, LDH, haptoglobin, DAT, PT, APTT, fibrinogen and D-dimer are interpreted as a pattern; thrombocytopenic fragmentation may require urgent ADAMTS13 sampling.
05
Renal, liver, viral and inflammation tests
Why
Detect systemic disease, organ consequences and secondary marrow suppression.
Interpretation and limitations
Select HIV, hepatitis, EBV, CMV, parvovirus or other testing from exposure and immune status. Liver disease may combine low thrombopoietin, bleeding and hypersplenism.
06
Bone-marrow aspirate and trephine
Why
Assess cellularity, dysplasia, infiltration, fibrosis, haemophagocytosis and clonal disease.
Interpretation and limitations
Coordinate morphology, flow, cytogenetics and molecular samples. A dry tap increases concern for fibrosis or packed marrow and makes trephine quality essential.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Acute leukaemia

Blasts, abnormal promyelocytes, rapid count change, bone pain, organ enlargement, infection or bleeding support acute leukaemia even when circulating blasts are initially absent.

Aplastic anaemia

Marked cytopenias, very low reticulocytes and a hypocellular marrow without malignant infiltration support aplasia after inherited, drug, viral and immune causes are assessed.

Megaloblastic deficiency

Macro-ovalocytes, hypersegmented neutrophils, low B12 or folate and high LDH with an inadequate reticulocyte response indicate ineffective haematopoiesis.

Hypersplenism

Splenomegaly with portal, infective or haematological disease and preserved or increased marrow activity supports sequestration rather than primary empty-marrow failure.

Consumptive systemic illness

Sepsis, DIC, TMA and haemophagocytic syndromes cause acute cytopenias with inflammatory, coagulation, haemolytic or organ-failure evidence beyond the marrow count.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01UnwellTreat infection, bleeding and hypoxiaFirst stepPancytopenia accompanies fever, sepsis, active bleeding, neurological change, chest pain, syncope or haemodynamic instability.

1Use ABCDE, cultures and urgent blood tests, examine for bleeding and infection, and contact haematology and transfusion early while preserving film, flow, coagulation and haemolysis samples.
2First lineFirst-line treatment follows the emergency phenotype: immediate guideline antibiotics for neutropenic sepsis, major-haemorrhage support for significant bleeding, and symptom-led red-cell support rather than delay for final marrow classification.
3EscalationEscalate abnormal promyelocytes, DIC, leukostasis, TMA, shock or organ ischaemia to critical care and the appropriate specialist pathway; avoid prophylactic correction unsupported by bleeding or procedure guidance.

02MechanismSeparate low output from peripheral lossThe patient is stable enough for a structured causal work-up after immediate threats are addressed.

1Obtain repeat FBC, film and absolute reticulocytes, then review medicines, alcohol, nutrition, infection, liver disease, autoimmunity, cancer, travel and spleen findings.
2AlternativeLow reticulocytes favour a production pathway with haematinics and early marrow consideration; a regenerative response favours the alternative haemolysis, bleeding, consumption or hypersplenism pathway.
3EscalationTreat a confirmed reversible cause and define an early count-response check; escalate diagnostic uncertainty, progressive decline or abnormal morphology instead of extending empirical supplements.

03MarrowSecure definitive tissueDefinitivePersistent unexplained pancytopenia, blasts, a leucoerythroblastic film or profound reticulocytopenia suggests serious marrow disease.

1Discuss urgently with haematology, complete necessary blood flow, viral, nutritional and molecular samples, and review haemostasis and transfusion needs before biopsy.
2PreferredAlternativeThe preferred diagnostic procedure is coordinated aspirate plus trephine with morphology, flow, cytogenetic and molecular allocation; alternative tissue or repeat sampling follows only if the first specimen cannot answer the question.
3EscalationEscalate preliminary acute leukaemia, aplasia or aggressive infiltration results immediately and maintain infection, bleeding and tumour-lysis surveillance while the integrated report is completed.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Life-threatening infection

Severe neutropenia can blunt pus, fever and local signs, allowing bacterial or fungal infection to progress rapidly to shock.

Major bleeding

Thrombocytopenia, platelet dysfunction or concurrent coagulopathy can cause clinically important mucosal, gastrointestinal, pulmonary or intracranial haemorrhage.

Tissue hypoxia

Severe or rapidly developing anaemia causes myocardial ischaemia, syncope, heart failure and reduced organ oxygen delivery.

Clonal progression

Myelodysplasia, marrow-failure syndromes and clonal haematopoiesis can evolve into acute myeloid leukaemia or deeper marrow failure.

Treatment-related harm

Transfusions, antimicrobials and immunosuppression can cause reactions, alloimmunisation, infection, iron loading or organ toxicity during prolonged supportive care.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Trend haemoglobin, absolute neutrophils and platelets separately because each lineage recovers at a different rate and carries a different immediate risk.
During fever or instability, repeat observations, lactate, renal and liver function and cultures through the sepsis pathway; absence of fever does not exclude infection in profound neutropenia.
Document bleeding, menstrual loss, stool or urine blood and neurological symptoms alongside platelets and coagulation rather than monitoring the count alone.
Use reticulocyte recovery, LDH and the confirmed mechanism to judge response after haematinic treatment, drug withdrawal or control of peripheral consumption.
Track marrow morphology, flow, cytogenetic and molecular addenda to a named haematology team and communicate any preliminary acute-leukaemia result directly.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

Three lines suggest one system

Multilineage reduction should first prompt a unifying marrow, systemic or splenic mechanism, while still allowing two common disorders to coexist.

High LDH is not automatically haemolysis

Ineffective megaloblastic precursors can die within marrow and release LDH. Low reticulocytes distinguish this from an appropriate peripheral haemolytic response.

Splenomegaly argues against simple aplasia

Marked spleen enlargement suggests sequestration, infiltration or clonal disease and should make isolated acquired aplastic anaemia less likely.

Aleukaemic leukaemia exists

Acute leukaemia can remain predominantly marrow based, so absence of circulating blasts does not close the diagnosis in progressive unexplained pancytopenia.

Support can change the sample

Transfusion and corticosteroids alter morphology, indices and clonality assessment. Take diagnostic material first when safe, without compromising emergency treatment.

11Common pitfallsFrequent interpretation and management errors.

01
Treating anaemia alone while ignoring simultaneous neutropenia and thrombocytopenia.
02
Assuming absence of blasts on one film excludes acute leukaemia.
03
Giving folic acid before considering B12 deficiency in a patient with neurological symptoms.
04
Calling low counts hypersplenism without demonstrating splenomegaly and excluding marrow disease.
05
Waiting for fever in a profoundly neutropenic patient with shock or focal infection.
06
Delaying marrow referral through repeated empirical haematinic courses without response.
07
Failing to review medicines, alcohol, supplements and occupational or recreational toxins.